(press release 1/15/2021) (Peer Reviewed)
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. NCT04381936
Recovery Collaborative Group et al., 1/15/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 1 author.
risk of death, no change, RR 1.00, p = 0.95, treatment 1399 of 5795 (24.1%), control 1408 of 5763 (24.4%), day 28.
risk of no hospital discharge, 1.0% higher, RR 1.01, p = 0.57, treatment 1963 of 5795 (33.9%), control 1941 of 5763 (33.7%), day 28.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.